Scientific Program

09:00-09:40 Plenary 3: Genome Editing
09:00-09:40

PL03 Organellar DNA Editing in Vitro and in Vivo

Jin-Soo Kim (KAIST, Korea)
09:40-10:55 Session 5. RNA & Genome Editing
09:40-10:05 S05-1 Wensheng Wei (Peking University, China)
10:05-10:30

S05-2 High-Resolution RNA Knockdown Profiles of Small RNA and Cas13 Systems

S. Chul Kwon (The University of Hong Kong, Hong Kong, China)
10:30-10:55 S05-3 Seung Ryul Han (Rznomics, Korea)
11:15-12:15 Session 6. Short Talks (Selected from Abstracts)
11:15-11:25

S06-1 Enhancing Translational Validity: Integrating Welfare, Behavioral Enrichment, and the 3Rs into Non-Human Primate Models for Oligonucleotide Therapeutics Development

Hanna Suh (Korea Institute of Toxicology, Korea)
11:25-11:35 S06-2 TBD
11:35-11:45 S06-3 TBD
11:45-11:55 S06-4 TBD
11:55-12:05 S06-5 TBD
12:05-12:15 S06-6 TBD
12:15-13:15 Lunch Seminar 2 [LS2]
12:15-13:15

LS2 From AI-Driven Discovery to Efficient RNA Synthesis: Advancing Productivity With MerMade Oligo Synthesizers and PrimeMax CPG Solid Support

Ralph Walker II (LGC Diagnostics & Genomics, USA)
13:15-13:55 Plenary 4: Aptamer Therapeutics & Clinical Translation
13:15-13:55

PL04 Preclinical and Clinical Development of Anticoagulant and Thrombolytic Aptamers and Reversal Agents

Bruce Sullenger (Duke University, USA)
13:55-15:15 Session 7. Aptamers & ASO
13:55-14:20

S07-1 Novel DNA Modality: Genetic Alphabet Expansion

Ichiro Hirao (Xenolis Pte Ltd, Singapore)
14:20-14:45

S07-2 Addressing Key Challenges in Oligonucleotide Therapeutics with Luxna Xeno Nucleic Acid (XNA) Technologies

Ryohei Kajino (Luxna Biotech, Japan)
14:45-15:00

S07-3 Brain Somatic Mosaicism: A Platform for RNA Therapeutic Target Discovery in Neurological Disorders

Jeong Ho Lee (KAIST / Sovargen, Korea)
15:00-15:15 S07-4 Il-Hoan Oh (RegenInnopharm, Korea)
15:35-17:15 Session 8. Oligonucleotide Development — Tox, CMC & Regulatory
15:35-16:00 S08-1 Yogesh S. Sanghvi (Rasayan Inc., USA)
16:00-16:25

S08-2 The Impurity Puzzle: Connecting Process, Quality, and Regulatory Strategy

Thomas Rupp (Thomas Rupp Consulting UG, Germany)
16:25-16:50

S08-3 Zilganersen in Alexander Disease: Translational Pharmacology, CNS Delivery, and Intrathecal Safety

Tae-Won Kim (Ionis Pharmaceuticals, USA)
16:50-17:15

S08-4 From Chiral Monomers to Stereopure Oligonucleotides: Synthesis and NMR Characterization

Ik-Hyeon Paik (Wave Life Sciences, USA)
TOP